01 March 2004
Med Sci Monit 2004; 10(3): BR84-89 :: ID: 11601
Background:Cyclophosphamide (CP) is used in the treatment of autoimmune disorders and leukemia. The compound induces severe leuko- and neutropenia. Lactoferrin (LF) is a protein which plays a role in the innate immunity. In this study we evaluated the usefulness of LF in reversing CP-induced lympho- and neutropenia in mice.Material/Methods: CBA mice were treated with CP (350 mg/kg body weight, intraperitoneally) and given LF as a 0.5% addition to drinking water. Alternatively, LF was administered orally (seven doses, 1 mg each) on alternate days following CP injection. Control groups received CP or LF only. Blood samples were taken before treatment and on days 4, 8, 15 and 22 following CP injection to determine leukocytosis and cell types in blood smears.Results: Mice treated with CP showed severe leukopenia, strong eosinophilia (day 4), and an altered lymphocyte/neutrophil ratio (days 8–22). Treatment of mice with LF for 21 days partially normalized the cell composition in CP-treated mice (increased percentage of lymphocytes and decreased eosinophil content). The content of leukocytes increased upon LF treatment on days 4, 8, 15 and 22 (by 36.8, 39.5, 72 and 70.7%, respectively). More importantly, LF partly normalized the neutrophil and lymphocyte composition on day 22 (neutrophils: 29.2% in control mice, 50.6% in CP-treated, and 39.16% in CP/LF-treated; lymphocytes: 66.18% in control mice, 35% in CP-treated and 48.8% in CP/LF-treated). Administration of LF alone did not change the cell numbers or composition.Conclusions: LF given orally to CP-immunocompromised mice accelerates reconstitution of lymphopoiesis and myleopoiesis.
Keywords: Body Weight, Cyclophosphamide - pharmacology, Eosinophils - drug effects, Immunosuppressive Agents - pharmacology, Lactoferrin - metabolism, Lactoferrin - pharmacology, Leukocytosis - metabolism, Lymphocytes - drug effects, Lymphopenia - drug therapy, Mice, Inbred CBA, Myelopoiesis, Neutropenia - drug therapy, Neutrophils - drug effects, Time Factors, Body Weight, Cyclophosphamide - pharmacology, Eosinophils - drug effects, Immunosuppressive Agents - pharmacology, Lactoferrin - pharmacology, Leukocytosis - metabolism, Lymphocytes - drug effects, Lymphopenia - drug therapy, Mice, Inbred CBA, Myelopoiesis, Neutropenia - drug therapy, Neutrophils - drug effects, Time Factors
01 November 2023 : EditorialEditorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared
Med Sci Monit 2023; 29:e942960
30 Nov 2023 : Review articleDecoding the Neurological Sequelae of General Anesthesia: A Review
Med Sci Monit In Press; DOI: 10.12659/MSM.942740
30 Nov 2023 : Clinical ResearchEnhanced Pain Relief and Muscle Growth in Individuals with Low Back Instability: The Impact of Blood Flow R...
Med Sci Monit In Press; DOI: 10.12659/MSM.942508
29 Nov 2023 : Clinical ResearchComparative Analysis of Intramedullary Nail versus Plate Fixation for Fibula Fracture in Supination Externa...
Med Sci Monit In Press; DOI: 10.12659/MSM.941909
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical ResearchPrevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292